Genmab — Juli 2017
-
@E L Thanks for the Novartis CAR-T link. Interesting what will happen to this technology. Some appear to believe that KITE will benefit from the Novartis hearing http://www.investors.com/news/technology/novartis-is-going-before-the-fda-but-kite-could-benefit-more/?src=A00220&yptr=yahoo
-
God morgen :-9
-
Ved en investorpræsentatione for nogle måneder siden sagde Jan, at telefonen hos Janssen var rødglødende, for der var så mange der ville lave kombinationer med Daratumumab. Umiddelbart er jeg en lille smule skuffet over der ikke sker mere - hvad tænker i andre ?
-
-
-
-
LY3164530
LY3164530 is a bispecific anti-EGFR/cMET antibody generated by fusing an anti-EGFR single-chain variable fragment (humanized cetuximab sequence) to the N-terminus of the emibetuzumab heavy chain. LY3164530 binds and internalizes cMET and EGFR without agonistic activity. In a NSCLC xenograft model, LY3164530 showed better antitumor efficacy than combination treatment with emibetuzumab and cetuximab.32 A phase I clinical study is ongoing (NCT02221882).
-
JNJ-61186372
The bispecific EGFR/cMET antibody JNJ-61186372 is a heterodimeric IgG1 composed of two units targeting EGFR and cMET.33 The cMET-binding IgG1 molecule is generated with a K490R mutation in the CH3 domain and the EGFR-binding IgG1 molecule is generated with a F405L mutation in the CH3 domain.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind